熱門資訊> 正文

enGene Holdings GAAP每股收益0.44美元

2026-03-10 01:25

enGene Holdings(ENGN) 0
Crescent Biopharma(CBIO) 0

enGene Holdings press release (ENGN): Q1 GAAP EPS of $0.44.
As of January 31, 2026, cash, cash equivalents and marketable securities were $312.5 million.
Total operating expenses were $31.2 million for the three months ended January 31, 2026, compared to $26.6 million for 2025.

More on enGene Holdings

enGene: Two Major Catalysts On Deck For 2nd Half Of 2026
enGene Holdings: A Potential Oncology Entrant
enGene extends momentum with another 14% surge on Friday
enGene Holdings GAAP EPS of $2.29
Seeking Alpha’s Quant Rating on enGene Holdings

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。